About 100 million people worldwide have type II diabetes (T2D), making it one of the most common metabolic diseases. DPP-IV (dipeptidyl peptidase-IV) inhibitors are new class anti-diabetic drugs. Gold complexes known for diverse biological activities. Considering these precedents, and growing interest in developing metal-based enzyme inhibitors, we report here inhibitory potential cationic, neu...

Methylene blue (MB) is used in human therapy various pathological conditions. Its effects neurodegenerative disease models are promising. MB acts on multiple cellular targets and mechanisms, but many of its potential beneficial ascribed to be mitochondrial. According the “alternative electron transport” hypothesis, capable donating electrons cytochrome c bypassing complex I III. As a consequenc...

Tyrosine kinase inhibitors (TKIs) are emerging as potentially effective options in the treatment of cancer, acting on pathways involved growth, avoidance apoptosis, invasiveness, angiogenesis, and local distant spread. TKIs induce significant adverse effects, that can negatively affect patients’ quality life. The most common events (AEs) include fatigue, hand–foot skin reaction, decreased appet...